DBD Diebold Nixdorf Forecast, Technical & Fundamental Analysis

Momentum Indicator for DBD turns negative, indicating new downward trend

DBD saw its Momentum Indicator move below the 0 level on September 04, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 53 similar instances where the indicator turned negative. In 35 of the 53 cases, the stock moved further down in the following days. The odds of a decline are at 66%.

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DBD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 58%.

The Aroon Indicator for DBD entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where DBD's RSI Indicator exited the oversold zone, 9 of 11 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for DBD just turned positive on August 28, 2026. Looking at past instances where DBD's MACD turned positive, the stock continued to rise in 22 of 31 cases over the following month. The odds of a continued upward trend are 71%.

Following a +1.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where DBD advanced for three days, in 173 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

DBD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.255) is normal, around the industry mean (51.950). P/E Ratio (21.321) is within average values for comparable stocks, (82.426). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.152). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.606) is also within normal values, averaging (70.180).

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. DBD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DBD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.